Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Jul 10, 2024 (2 years ago)

Clonazepam Orally Disintegrating Tablets

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled as 0.125 mg instead of 0.25 mg. The blister strips inside the product carton reflect the correct strength of 0.25 mg.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.125mg, 60 tablets per carton (10 blister cards containing 6 tablets each), Rx Only, Distributed by: Par Pharmaceutical, Chestnut Ridge, NY 10977, NDC# 49884-306-02.

Affected NDC 49884-0306-02

Compare with the code on your package — it is the most precise check available.

Drug: Clonazepam Category: Mental Health Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Clonazepam
NDC 49884-0306
.125 mg/1 Tablet, Orally Disintegrating
Oral
Par Health USA, LLC Rx · CIV
Recalling firm
Endo Pharmaceuticals, Inc.
NDC code
49884-306-02
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
Company announcement
Jul 16, 2024 · FDA notice with lot numbers
FDA recall number
D-0622-2024 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Clonazepam recalls

See all
Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0181-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0180-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablets

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0179-2025
Class I · High risk

Clonazepam Orally Disintegrating Tablet

Labeling: Label Error on Declared Strength; Some cartons were incorrectly labeled. The blister strips inside the product carton reflect the correct strength.

Ongoing Labeling / mix-up Endo USA, Inc. D-0178-2025

Other recalls by Endo Pharmaceuticals, Inc.

All 2024 recalls
Class II · Moderate risk

Calcitonin Salmon Nasal Spray

Failed Impurities/Degradation Specifications and Subpotent Drug: High Out of Specification results for a known and unknown impurity as well as low Out of Specification results for assay.

Terminated Impurity / degradation Endo Pharmaceuticals, Inc. NDC 49884-161-11 D-0475-2023
Class I · High risk

robaxin-750

Labeling: Incorrect Instructions: Dosage information on the immediate container label incorrectly states "Two to four tablets four times daily." rather than the correct dosage of "Two tablets three times daily."

Terminated Labeling / mix-up Endo Pharmaceuticals, Inc. NDC 52244-449-10 D-0009-2019
Class III · Low risk

Endocet (oxycodone and acetaminophen)

Adulterated Presence of Foreign Tablets: Customer complaint that some Endocet 10 mg/325 mg tablets were found mixed in a bottle with Endocet 10 mg/650 mg tablets.

Terminated Particulate / foreign matter Endo Pharmaceuticals, Inc. NDC 60951-797-70 D-1381-2012